

Approved



Caribbean Region
Country Operational Plan
FY 2016



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		399,544		399,544	94,962	494,506
USAID		4,845,010	6,536,628	11,381,638	3,121,254	14,502,892
DOD		0		0	798,000	798,000
PC		0		0	119,587	119,587
HHS/CDC	1,593,750	6,798,711		8,392,461	2,766,696	11,159,157
HHS/HRSA		2,008,000		2,008,000	0	2,008,000
State/WHA		200,000		200,000	0	200,000
Total	1,593,750	14,251,265	6,536,628	22,381,643	6,900,499	29,282,142

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							On Hold Amount	Total
	State	State/WHA	DOD	HHS/CDC	HHS/HRSA	PC	USAID		
HBHC			0	231,319	288,000		4,256,678	0	4,775,997
HKID							105,688	0	105,688
HLAB			0	1,663,465				0	1,663,465
HTXS				616,480	1,669,935		906,707	0	3,193,122
HVCT			0	187,745			782,506	0	970,251
HVMS	399,544		0	2,758,257		0	1,170,462	0	4,328,263
HVOP		200,000	0	89,329		0	1,439,708	0	1,729,037
HVSI	0		0	2,595,350			217,572	0	2,812,922
HVTB							0	0	0
MTCT				0				0	0

Approved



OHSS				172,898	50,065	0	2,502,317	0	2,725,280
PDCS				13,364				0	13,364
PDTX				64,254				0	64,254
	399,544	200,000	0	8,392,461	2,008,000	0	11,381,638	0	22,381,643



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	4,588,904	0
HKID	97,193	0
PDCS	13,364	0
Total Technical Area Planned Funding:	4,699,461	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	1,368,681	0
HVSI	2,074,417	0
OHSS	2,556,456	0
Total Technical Area Planned Funding:	5,999,554	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HVCT	827,335	0
HVOP	1,565,368	0
MTCT	0	
Total Technical Area Planned Funding:	2,392,703	0

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXS	3,093,638	0

Approved



PDTX	64,254	0
Total Technical Area Planned Funding:	3,157,892	0

Approved



Technical Area Summary Indicators and Targets

Antigua and Barbuda

(No data provided.)



Technical Area Summary Indicators and Targets

Bahamas

Indicator Number	Label	2017
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,102
	Total estimated number of key population in the catchment area	4,409
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet	372



	the minimum standards required)	
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	730
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key	



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	1,489
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key	2,920



	population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	882
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	



	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex:	



	Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	294
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	588
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age	



	and Sex: Positive <15 Male	
	Test Result by Aggregated Age and Sex: Positive 15+ Male	18
	Test Result by Aggregated Age and Sex: Positive <15 Female	
	Test Result by Aggregated Age and Sex: Positive 15+ Female	30
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community)	



	by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility): Outpatient	
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	
	Service Delivery Point (Facility): VCT	
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by	



	Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	240
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	



	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	114
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	126
	Sum of Aggregated Age/Sex	240



	disaggregates	
	Pregnancy status	
	Breastfeeding status	
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	CD4: Number of laboratories that participate in this PT program	1
	CD4: Number of laboratories that perform this testing	1
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	Early infant diagnostics: Number of laboratories that participate in this PT program	1
	Early infant diagnostics: Number of laboratories that perform this testing	1
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	4
	HIV serologic/diagnostic testing: Number of laboratories that	4



	perform this testing	
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	HIV viral load: Number of laboratories that participate in this PT program	1
	HIV viral load: Number of laboratories that perform this testing	1
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	1
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	1
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0



	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	1,333
	Number of HIV Test Kits purchased	
	Number of HIV CD4 Reagents purchased	
	Number of Condoms purchased	
	Number of HIV Viral Load Reagents purchased	1,333
	Number of HIV ARVs purchased	
	Number of Second Line HIV ARVs purchased	
	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	
	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	
	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	40,000
	Condoms: Dollars planned (COP)/ spent (Actual)	
	HIV ARVs: Dollars planned (COP)/ spent (Actual)	



Technical Area Summary Indicators and Targets

Barbados

Indicator Number	Label	2017
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,578
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	899
	Aggregated Age/Sex: <15 Female	
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	679
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	1,578
	Sum of Aggregated Age/Sex disaggregates	1,578



	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
	TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)
By Age/Sex: <1		
By Age/Sex: 1-9		
By Age/Sex: 10-14 Male		
By Age/Sex: 15-19 Male		
By Age/Sex: 20-24 Male		
By Age/Sex: 25-49 Male		
By Age/Sex: 50+ Male		
By Age/Sex: 10-14 Female		
By Age/Sex: 15-19 Female		
By Age/Sex: 20-24 Female		
By Age/Sex: 25-49 Female		
By Age/Sex: 50+ Female		
Sum of Age/Sex disaggregates		
Aggregated Grouping by Age: <1		
Aggregated Grouping by Age: <1 Male		
Aggregated Grouping by Age/Sex:		



	<15 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	82
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	82
	Sum of Aggregated Age/Sex disaggregates	164
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	



	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	0
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	6
	Sum of Aggregated Age/Sex disaggregates	6
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a



	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,262
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,578
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	



	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	



	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	
	Numerator: Indication: Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	
	Denominator: Indication: Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	



	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	



	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	
	Numerator Aggregated Age/Sex: 15+ Male	719
	Numerator Aggregated Age/Sex: <15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	543
	Denominator Aggregated Age/Sex: <15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	899



	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	679
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	CD4: Number of laboratories that participate in this PT program	1
	CD4: Number of laboratories that perform this testing	1
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	Early infant diagnostics: Number of laboratories that participate in this PT program	1
	Early infant diagnostics: Number of laboratories that perform this testing	1
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	5
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	5
	HIV serologic/diagnostic testing:	5



	Number of laboratories that perform this testing	
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	HIV viral load: Number of laboratories that participate in this PT program	1
	HIV viral load: Number of laboratories that perform this testing	1
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	1
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	1
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful	0



	passing criteria in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	500
	Number of HIV Test Kits purchased	
	Number of HIV CD4 Reagents purchased	
	Number of Condoms purchased	
	Number of HIV Viral Load Reagents purchased	500
	Number of HIV ARVs purchased	
	Number of Second Line HIV ARVs purchased	
	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	
	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	
	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	25,000
	Condoms: Dollars planned (COP)/ spent (Actual)	
	HIV ARVs: Dollars planned (COP)/ spent (Actual)	

Approved



Technical Area Summary Indicators and Targets

Belize - Caribbean

(No data provided.)

Approved



Technical Area Summary Indicators and Targets

Dominica

(No data provided.)

Approved



Technical Area Summary Indicators and Targets

Grenada

(No data provided.)

Technical Area Summary Indicators and Targets

Guyana

Indicator Number	Label	2017
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,652
	Total estimated number of key population in the catchment area	3,658
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet	1,286



	the minimum standards required)	
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,366
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key	



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	1,837
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key	1,821



	population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,607
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	



	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
Test Result by Age and Sex:		



	Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	83
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,019
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	73
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,432
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	6
	Test Result by Aggregated Age	99



	and Sex: Positive 15+ Male	
	Test Result by Aggregated Age and Sex: Positive <15 Female	4
	Test Result by Aggregated Age and Sex: Positive 15+ Female	101
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	150
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	1,739
	Service Delivery Point (Community): Other	763
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility):	



	Inpatient	
	Service Delivery Point (Facility): Outpatient	
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	1,655
	Service Delivery Point (Facility): VCT	
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	300
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by	



	Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	162
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	52



	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	83
	Sum of Age/Sex disaggregates	135
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	



	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	
	Required only for DREAMS	



	countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	



	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and	



	sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	



	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	
	Program Completion: Active	
	Program Completion: Graduation	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	



	By Aggregated Age/Sex: <18 Male	12
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	15
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	1,718
	Screened for TB by Age/Sex:<15 Male	9
	Screened for TB by Age/Sex: 15+ Male	644
	Screened for TB by Age/Sex:<15 Female	35
	Screened for TB by Age/Sex: 15+	1,030



	Female	
	Screen Result: Screened Positive for TB	35
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	35
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	27
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	8
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	1,861
	Screened for TB by Age/Sex: <15 Male	100
	Screened for TB by Age/Sex: 15+ Male	837
	Screened for TB by Age/Sex: <15 Female	94
	Screened for TB by Age/Sex: 15+ Female	830
	Screen Results: Screened Positive for TB	38
	TB Positive by Age/Sex: <15 Male	



	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	38
	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	29
	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	9
	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	38
	By infants who received their first virologic HIV test between 2 and 12 months of age	2
	Sum of Infant Age disaggregates	40
	By infants with a positive virologic test result within 12 months of birth	



	Number of infants with a positive virological test result within 2 months of birth	0
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,718
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	9
	Aggregated Age/Sex: 15+ Male	644
	Aggregated Age/Sex: <15 Female	35
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	1,030
	Sum of Aggregated Age/Sex <15	44
	Sum of Aggregated Age/Sex 15+	1,674
	Sum of Aggregated Age/Sex disaggregates	1,718
	Age/Sex: <1	
Age/Sex: <1-9		



	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,861
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	94
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	830
Aggregated Age/Sex: <15 Female	100	
Aggregated Age/Sex: 1-14 Female		



	Aggregated Age/Sex: 15+ Female	837
	Sum of Aggregated Age/Sex <15	194
	Sum of Aggregated Age/Sex 15+	1,667
	Sum of Aggregated Age/Sex disaggregates	1,861
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	322
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	



	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	2
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	147
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	2
	Aggregated Grouping by Age/Sex: 15+ Female	171
	Sum of Aggregated Age/Sex disaggregates	322
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	349
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	



	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	2
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	163
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	2
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	182
	Sum of Aggregated Age/Sex disaggregates	349
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of	n/a



	ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,160
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,546
	Numerator: Indication: Routine	1,160
	Numerator: Indication: Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	



	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	



	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	1,546
	Denominator: Indication: Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	



	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	



	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	29
	Numerator Aggregated Age/Sex: 15+ Male	543
	Numerator Aggregated Age/Sex: <15 Female	29



	Numerator Aggregated Age/Sex: 15+ Female	559
	Denominator Aggregated Age/Sex: <15 Male	38
	Denominator Aggregated Age/Sex: 15+ Male	715
	Denominator Aggregated Age/Sex: <15 Female	40
	Denominator Aggregated Age/Sex: 15+ Female	753
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,256
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,675
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication:	
	Numerator: Age/Sex by Indication:	



	1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication:	



	50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	1,256
	Numerator: Indication: Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	1,675



	Denominator: Indication: Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by	



	Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by	



	Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	51
	Numerator Aggregated Age/Sex: 15+ Male	549
	Numerator Aggregated Age/Sex: <15 Female	73
	Numerator Aggregated Age/Sex: 15+ Female	583
	Denominator Aggregated Age/Sex: <15 Male	77
	Denominator Aggregated Age/Sex: 15+ Male	745
	Denominator Aggregated Age/Sex: <15 Female	91
	Denominator Aggregated Age/Sex: 15+ Female	762
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	151
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	178



	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and	



	children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	



	including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female	



	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	



	including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and	7



	children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	64
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	72
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	76
	Aggregated Age/Sex: <15 Female (Denominator: Total number of	10



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	84
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	200
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	227
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	



	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	



	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	



	including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female	



	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator:)	



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	86



	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	94
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	95
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of	109

Approved



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
--	--	--



Technical Area Summary Indicators and Targets

Jamaica

Indicator Number	Label	2017
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,085
	Total estimated number of key population in the catchment area	32,371
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet	1,268



	the minimum standards required)	
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	817
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key	



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	18,754
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key	13,617



	population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
KP_PREV_TA	KP_PREV_TA Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (TA-only)	n/a
	Number of key populations reached with individual and/or small group	118



	level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	
	Total estimated number of key population in the catchment area	376
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID)	



	(Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men and are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	118
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with	



	individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men and are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	376
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the	



	catchment area)	
	By Service: KP known positive	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: Returning beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,859
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
Test Result by Age and Sex: Positive: 20-24 Male		



	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	



Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,124
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	735
Test Result by Aggregated Age and Sex: Negative <15 Male	
Test Result by Aggregated Age and Sex: Negative 15+ Male	
Test Result by Aggregated Age and Sex: Negative <15 Female	
Test Result by Aggregated Age and Sex: Negative 15+ Female	
Test Result by Aggregated Age and Sex: Positive <15 Male	
Test Result by Aggregated Age and Sex: Positive 15+ Male	120
Test Result by Aggregated Age and Sex: Positive <15 Female	
Test Result by Aggregated Age and Sex: Positive 15+ Female	22
Test Result by Age: Positive: <1	
Test Result by Age: Positive: 1-9	
Age/sex: <1	
Age/sex: 1-9	
Service Delivery Point (Community): Index testing	
Service Delivery Point (Community): Homebased testing	



	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	1,799
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility): Outpatient	
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	
	Service Delivery Point (Facility): VCT	
	Service Delivery Point (Facility): VMMC	



	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	



	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	94
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
Test Result by Age and Sex:		



	Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex:	



	Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	94
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	
	Test Result by Aggregated Age and Sex: Positive 15+ Male	14
	Test Result by Aggregated Age and Sex: Positive <15 Female	
	Test Result by Aggregated Age and Sex: Positive 15+ Female	
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point	



	(Community): Index testing	
	Service Delivery Point	
	(Community): Homebased testing	
	Service Delivery Point	
	(Community): Mobile testing	
	Service Delivery Point	14
	(Community): Other	
	Service Delivery Point (Community)	
	by Age: <15 index testing	
	Service Delivery Point (Community)	
	by Age: 15+ index testing	
	Service Delivery Point (Community)	
	by Age: <15 homebased testing	
	Service Delivery Point (Community)	
	by Age: 15+ homebased testing	
	Service Delivery Point (Community)	
	by Age: <15 mobile testing	
	Service Delivery Point (Community)	
	by Age: 15+ mobile testing	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Facility):	
	Inpatient	
	Service Delivery Point (Facility):	
	Outpatient	
	Service Delivery Point (Facility):	
	Pediatric	
	Service Delivery Point (Facility):	
	Malnutrition facilities	
	Service Delivery Point (Facility):	
	Other PITC	
	Service Delivery Point (Facility):	



	VCT	
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by	



	Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	12,728
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	
Aggregated Age/Sex: 1-14 Male		



	Aggregated Age/Sex: 15+ Male	6,109
	Aggregated Age/Sex: <15 Female	
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	6,620
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	12,729
	Sum of Aggregated Age/Sex disaggregates	12,729
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,220
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	



	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	585
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	635
	Sum of Aggregated Age/Sex disaggregates	1,220
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,217
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	



	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	80
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	1,034
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	26
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	1,083
	Sum of Aggregated Age/Sex disaggregates	2,223



	Pregnancy status	
	Breastfeeding status	
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	10,181
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	12,728
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication:	



	10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by	



	Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	
	Numerator: Indication: Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	
	Denominator: Indication: Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by	



	Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by	



	Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	
	Numerator Aggregated Age/Sex:	4,886



	15+ Male	
	Numerator Aggregated Age/Sex: <15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	5,295
	Denominator Aggregated Age/Sex: <15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	6,109
	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	6,619
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
	CD4: Number of laboratories that participate in this PT program	4
	CD4: Number of laboratories that perform this testing	4
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	Early infant diagnostics: Number of laboratories that participate in this PT program	1
	Early infant diagnostics: Number of laboratories that perform this	1



	testing	
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	18
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	18
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	18
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	HIV viral load: Number of laboratories that participate in this PT program	1
	HIV viral load: Number of laboratories that perform this testing	1
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	6
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	6
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	6
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0



	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	6
	By Graduates: Doctors	
	By Graduates: Nurses	
	By Graduates: Midwives	
	By Graduates: Social service workers	
	By Graduates: Laboratory professionals	
	By Graduates: Other	
	Sum of Graduates disaggreagtes	
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	6,299



	Number of HIV Test Kits purchased	1,889
	Number of HIV CD4 Reagents purchased	
	Number of Condoms purchased	
	Number of HIV Viral Load Reagents purchased	3,067
	Number of HIV ARVs purchased	1,343
	Number of Second Line HIV ARVs purchased	
	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	10,198
	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	50,000
	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	130,580
	Condoms: Dollars planned (COP)/ spent (Actual)	
	HIV ARVs: Dollars planned (COP)/ spent (Actual)	161,160

Approved



Technical Area Summary Indicators and Targets

St. Kitts and Nevis

(No data provided.)

Approved



Technical Area Summary Indicators and Targets

St. Lucia

(No data provided.)

Approved



Technical Area Summary Indicators and Targets

St. Vincent and the Grenadines

(No data provided.)



Technical Area Summary Indicators and Targets

Suriname

Indicator Number	Label	2017
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,345
	Total estimated number of key population in the catchment area	9,260
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet	595



	the minimum standards required)	
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	750
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key	



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	6,800
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key	2,460



	population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	255
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	



	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
Test Result by Age and Sex:		



	Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	95
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	160
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	
	Test Result by Aggregated Age	10



	and Sex: Positive 15+ Male	
	Test Result by Aggregated Age and Sex: Positive <15 Female	
	Test Result by Aggregated Age and Sex: Positive 15+ Female	8
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	255
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility):	



	Inpatient	
	Service Delivery Point (Facility): Outpatient	
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	
	Service Delivery Point (Facility): VCT	
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by	



	Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	527
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	



	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex:	



	Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	234
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	293
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age	



	and Sex: Positive <15 Male	
	Test Result by Aggregated Age and Sex: Positive 15+ Male	14
	Test Result by Aggregated Age and Sex: Positive <15 Female	
	Test Result by Aggregated Age and Sex: Positive 15+ Female	14
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community)	



	by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility): Outpatient	
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	
	Service Delivery Point (Facility): VCT	95
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by	



	Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
	TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)
Age/Sex: <1 Male		
Age/Sex: 1-4 Male		
Age/Sex: 5-14 Male		
Age/Sex: 15-19 Male		



	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	231
	Aggregated Age/Sex: <15 Female	
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	233
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	464
	Sum of Aggregated Age/Sex disaggregates	464
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_TA	Number of adults and children	366



	newly enrolled on antiretroviral therapy (ART)	
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	184
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex:	



	<15 Female	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	182
	Sum of Aggregated Age/Sex disaggregates	366
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	325
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	464
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	



	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	



	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	
	Numerator: Indication: Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	
	Denominator: Indication: Targeted	



	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	



	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	



	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	
	Numerator Aggregated Age/Sex: 15+ Male	162
	Numerator Aggregated Age/Sex: <15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	163
	Denominator Aggregated Age/Sex: <15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	231
	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	233
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	CD4: Number of laboratories that participate in this PT program	1
	CD4: Number of laboratories that perform this testing	1
	Early infant diagnostics: Number of	1



	laboratories that achieve acceptable successful passing criteria in this PT program	
	Early infant diagnostics: Number of laboratories that participate in this PT program	1
	Early infant diagnostics: Number of laboratories that perform this testing	1
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	8
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	8
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	8
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	HIV viral load: Number of laboratories that participate in this PT program	1
	HIV viral load: Number of laboratories that perform this testing	1
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
	TB diagnostics (AFB microscopy): Number of laboratories that	3



	participate in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	3
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	2
	By Graduates: Doctors	
	By Graduates: Nurses	
	By Graduates: Midwives	
	By Graduates: Social service workers	



	By Graduates: Laboratory professionals	
	By Graduates: Other	
	Sum of Graduates disaggreagtes	
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	1,034
	Number of HIV Test Kits purchased	
	Number of HIV CD4 Reagents purchased	
	Number of Condoms purchased	
	Number of HIV Viral Load Reagents purchased	1,034
	Number of HIV ARVs purchased	
	Number of Second Line HIV ARVs purchased	
	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	
	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	
	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	30,000
	Condoms: Dollars planned (COP)/ spent (Actual)	
	HIV ARVs: Dollars planned (COP)/ spent (Actual)	



Technical Area Summary Indicators and Targets

Trinidad and Tobago

Indicator Number	Label	2017
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,000
	Total estimated number of key population in the catchment area	17,444
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet	400



	the minimum standards required)	
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	600
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key	



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	6,616
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key	10,828



	population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	600
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	



	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
Test Result by Age and Sex:		



	Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	360
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	240
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age	



	and Sex: Positive <15 Male	
	Test Result by Aggregated Age and Sex: Positive 15+ Male	22
	Test Result by Aggregated Age and Sex: Positive <15 Female	
	Test Result by Aggregated Age and Sex: Positive 15+ Female	12
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community)	



	by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility): Outpatient	
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	
	Service Delivery Point (Facility): VCT	
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by	



	Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
	TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	



	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	645
	Aggregated Age/Sex: <15 Female	
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	646
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	1,291
	Sum of Aggregated Age/Sex disaggregates	1,291
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_TA	Number of adults and children	724



	newly enrolled on antiretroviral therapy (ART)	
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	374
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex:	



	<15 Female	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	350
	Sum of Aggregated Age/Sex disaggregates	724
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,162
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,291
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	



	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	



	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	
	Numerator: Indication: Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	
	Denominator: Indication: Targeted	



	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	



	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	



	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	
	Numerator Aggregated Age/Sex: 15+ Male	581
	Numerator Aggregated Age/Sex: <15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	581
	Denominator Aggregated Age/Sex: <15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	645
	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	646
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
	CD4: Number of laboratories that participate in this PT program	4
	CD4: Number of laboratories that perform this testing	4
	Early infant diagnostics: Number of	1



	laboratories that achieve acceptable successful passing criteria in this PT program	
	Early infant diagnostics: Number of laboratories that participate in this PT program	1
	Early infant diagnostics: Number of laboratories that perform this testing	1
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	9
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	9
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	HIV viral load: Number of laboratories that participate in this PT program	1
	HIV viral load: Number of laboratories that perform this testing	1
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	6
	TB diagnostics (AFB microscopy): Number of laboratories that	6



	participate in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	6
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	4
	By Graduates: Doctors	
	By Graduates: Nurses	
	By Graduates: Midwives	
	By Graduates: Social service workers	



	By Graduates: Laboratory professionals	
	By Graduates: Other	
	Sum of Graduates disaggreagtes	
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	1,764
	Number of HIV Test Kits purchased	
	Number of HIV CD4 Reagents purchased	
	Number of Condoms purchased	
	Number of HIV Viral Load Reagents purchased	1,764
	Number of HIV ARVs purchased	
	Number of Second Line HIV ARVs purchased	
	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	
	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	30,000
	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	60,000
	Condoms: Dollars planned (COP)/ spent (Actual)	
	HIV ARVs: Dollars planned (COP)/ spent (Actual)	



Technical Area Summary Indicators and Targets

Caribbean Region

Indicator Number	Label	2017
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	8,184
	Total estimated number of key population in the catchment area	67,142
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet	3,921



	the minimum standards required)	
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,263
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key	



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	35,496
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key	31,646



	population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
KP_PREV_TA	KP_PREV_TA Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (TA-only)	n/a
	Number of key populations reached with individual and/or small group	118



	level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	
	Total estimated number of key population in the catchment area	376
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID)	



	(Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men and are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	118
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with	



	individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men and are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	376
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the	



	catchment area)	
	By Service: KP known positive	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: Returning beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,721
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
Test Result by Age and Sex: Positive: 20-24 Male		



	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	



Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	83
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,238
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	73
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,327
Test Result by Aggregated Age and Sex: Negative <15 Male	
Test Result by Aggregated Age and Sex: Negative 15+ Male	
Test Result by Aggregated Age and Sex: Negative <15 Female	
Test Result by Aggregated Age and Sex: Negative 15+ Female	
Test Result by Aggregated Age and Sex: Positive <15 Male	6
Test Result by Aggregated Age and Sex: Positive 15+ Male	229
Test Result by Aggregated Age and Sex: Positive <15 Female	4
Test Result by Aggregated Age and Sex: Positive 15+ Female	131
Test Result by Age: Positive: <1	
Test Result by Age: Positive: 1-9	
Age/sex: <1	
Age/sex: 1-9	
Service Delivery Point (Community): Index testing	150
Service Delivery Point (Community): Homebased testing	



	Service Delivery Point (Community): Mobile testing	1,994
	Service Delivery Point (Community): Other	2,562
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility): Outpatient	
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	1,655
	Service Delivery Point (Facility): VCT	
	Service Delivery Point (Facility): VMMC	



	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	300
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	



	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,103
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
Test Result by Age and Sex:		



	Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex:	



	Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	982
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,121
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	
	Test Result by Aggregated Age and Sex: Positive 15+ Male	68
	Test Result by Aggregated Age and Sex: Positive <15 Female	
	Test Result by Aggregated Age and Sex: Positive 15+ Female	56
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point	



	(Community): Index testing	
	Service Delivery Point	
	(Community): Homebased testing	
	Service Delivery Point	
	(Community): Mobile testing	
	Service Delivery Point	14
	(Community): Other	
	Service Delivery Point (Community)	
	by Age: <15 index testing	
	Service Delivery Point (Community)	
	by Age: 15+ index testing	
	Service Delivery Point (Community)	
	by Age: <15 homebased testing	
	Service Delivery Point (Community)	
	by Age: 15+ homebased testing	
	Service Delivery Point (Community)	
	by Age: <15 mobile testing	
	Service Delivery Point (Community)	
	by Age: 15+ mobile testing	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Facility):	
	Inpatient	
	Service Delivery Point (Facility):	
	Outpatient	
	Service Delivery Point (Facility):	
	Pediatric	
	Service Delivery Point (Facility):	
	Malnutrition facilities	
	Service Delivery Point (Facility):	
	Other PITC	
	Service Delivery Point (Facility):	95



	VCT	
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by	



	Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	162
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	52
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	83
	Sum of Age/Sex disaggregates	135
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	



	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	



	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs	



	Male 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS	



	countries - By service, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	



	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	



	Age/Sex: 1-9	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	
	Program Completion: Active	
	Program Completion: Graduation	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	
	By Aggregated Age/Sex: <18 Male	12
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	15
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS	



	countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	1,718
	Screened for TB by Age/Sex:<15 Male	9
	Screened for TB by Age/Sex: 15+ Male	644
	Screened for TB by Age/Sex:<15 Female	35
	Screened for TB by Age/Sex: 15+ Female	1,030
	Screen Result: Screened Positive for TB	35
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	



	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	35
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	27
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	8
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	1,861
	Screened for TB by Age/Sex: <15 Male	100
	Screened for TB by Age/Sex: 15+ Male	837
	Screened for TB by Age/Sex: <15 Female	94
	Screened for TB by Age/Sex: 15+ Female	830
	Screen Results: Screened Positive for TB	38
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	38
	[Sub-disagg of Specimen Sent]	29



	Diagnostic Test: Smear Only	
	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	9
	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	38
	By infants who received their first virologic HIV test between 2 and 12 months of age	2
	Sum of Infant Age disaggregates	40
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	0
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	



	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,718
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	9
	Aggregated Age/Sex: 15+ Male	644
	Aggregated Age/Sex: <15 Female	35
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	1,030
	Sum of Aggregated Age/Sex <15	44
	Sum of Aggregated Age/Sex 15+	1,674
	Sum of Aggregated Age/Sex disaggregates	1,718
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
Age/Sex: 50+ Male		



	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	17,922
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	94
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	8,714
	Aggregated Age/Sex: <15 Female	100
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	9,015
	Sum of Aggregated Age/Sex <15	194
	Sum of Aggregated Age/Sex 15+	17,729
	Sum of Aggregated Age/Sex disaggregates	17,923
	Age/Sex: <1	
Age/Sex: 1-9		
Age/Sex: 10-14 Male		



	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,706
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	2
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex:	814



	15+ Male	
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	2
	Aggregated Grouping by Age/Sex: 15+ Female	888
	Sum of Aggregated Age/Sex disaggregates	1,706
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,902
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
By Age/Sex: 25-49 Female		



	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	82
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	1,869
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	28
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	1,929
	Sum of Aggregated Age/Sex disaggregates	3,908
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records	1,160



	and /or supporting laboratory results within the past 12 months.	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,546
	Numerator: Indication: Routine	1,160
	Numerator: Indication: Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication:	



	15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by	



	Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	1,546
	Denominator: Indication: Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by	



	Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by	



	Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	29
	Numerator Aggregated Age/Sex: 15+ Male	543
	Numerator Aggregated Age/Sex: <15 Female	29
	Numerator Aggregated Age/Sex: 15+ Female	559
	Denominator Aggregated Age/Sex: <15 Male	38
	Denominator Aggregated Age/Sex: 15+ Male	715
	Denominator Aggregated Age/Sex: <15 Female	40
	Denominator Aggregated Age/Sex:	753



	15+ Female	
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	14,186
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	17,736
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	



	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	



	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	1,256
	Numerator: Indication: Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	1,675
	Denominator: Indication: Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	



	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	



	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	51
	Numerator Aggregated Age/Sex: 15+ Male	6,897



	Numerator Aggregated Age/Sex: <15 Female	73
	Numerator Aggregated Age/Sex: 15+ Female	7,165
	Denominator Aggregated Age/Sex: <15 Male	77
	Denominator Aggregated Age/Sex: 15+ Male	8,629
	Denominator Aggregated Age/Sex: <15 Female	91
	Denominator Aggregated Age/Sex: 15+ Female	8,939
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	151
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	178
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator:	



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female	



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	



	those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of	



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who	



	are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	64
	Aggregated Age/Sex: <15 Female	8



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	72
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	76
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated	84



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	200
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	227
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	



	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	



	<p>Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,</p>	



	those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of	



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	



	those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	86
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	94



	initiating ART)	
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	95
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	109
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate	



	and successfully pass in an analyte-specific proficiency testing (PT) program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	11
	CD4: Number of laboratories that participate in this PT program	11
	CD4: Number of laboratories that perform this testing	11
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	5
	Early infant diagnostics: Number of laboratories that participate in this PT program	5
	Early infant diagnostics: Number of laboratories that perform this testing	5
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	44
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	44
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	44
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	5
	HIV viral load: Number of	5



	laboratories that participate in this PT program	
	HIV viral load: Number of laboratories that perform this testing	5
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	17
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	17
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	17
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0



HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	12
	By Graduates: Doctors	
	By Graduates: Nurses	
	By Graduates: Midwives	
	By Graduates: Social service workers	
	By Graduates: Laboratory professionals	
	By Graduates: Other	
	Sum of Graduates disaggreagtes	
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	10,930
	Number of HIV Test Kits purchased	1,889
	Number of HIV CD4 Reagents purchased	
	Number of Condoms purchased	
	Number of HIV Viral Load Reagents purchased	7,698
	Number of HIV ARVs purchased	1,343
	Number of Second Line HIV ARVs purchased	
	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	10,198
	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	80,000
	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	285,580

Approved



	Condoms: Dollars planned (COP)/ spent (Actual)	
	HIV ARVs: Dollars planned (COP)/ spent (Actual)	161,160



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
12542	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	300,000
12567	Jamaica Ministry of Health (MOH)	Host Country Government Agency	U.S. Agency for International Development	GHP-State	3,105,000
12570	Bahamas MoH	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12575	Pan American Health Organization (PAHO)/PAHO HIV Caribbean Office (PHCO)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	350,000
12587	US Embassies	Other USG Agency	U.S. Department of State/Bureau of Western Hemisphere	GHP-State	200,000



			Affairs		
12588	Caribbean Community (CARICOM) Pan Caribbean Partnership Against AIDS	Multi-lateral Agency	U.S. Agency for International Development	GHP-USAID	200,000
12594	HRM	Other USG Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12606	Barbados MOH	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12642	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12645	World Learning	NGO	U.S. Agency for International Development	GHP-USAID	0
12668	Trinidad MoH	Host Country Government Agency	U.S. Department of Health and Human Services/Centers	GHP-State	0



			for Disease Control and Prevention		
12688	Caribbean Regional Public Health Agency	Parastatal	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12971	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	0
13319	Futures Group	Private Contractor	U.S. Agency for International Development	GHP-USAID	0
13335	African Field Epidemiology Network	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13534	National Alliance of State and Territorial AIDS Directors	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	250,000
13593	SURINAME MOH	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1



16482	Population Services International	NGO	U.S. Department of Defense	GHP-State	0
16661	Caribbean Regional Public Health Agency	Parastatal	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	366,938
17366	FHI 360	NGO	U.S. Agency for International Development	GHP-USAID	1,674,565
17469	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-USAID	675,000
17760	FHI 360	NGO	U.S. Agency for International Development	GHP-State	845,000
17808	TBD	TBD	Redacted	Redacted	Redacted
17809	Johns Hopkins University Center for Communication Programs	University	U.S. Agency for International Development	GHP-USAID	350,000
17810	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-USAID	0
17878	US Embassies	Other USG Agency	U.S. Agency for International Development	GHP-State	85,010
17902	Palladium Group	NGO	U.S. Agency for International Development	GHP-State	710,000
17919	African Society for	NGO	U.S. Department	GHP-State	0



	Laboratory Medicine		of Health and Human Services/Centers for Disease Control and Prevention		
17921	University of Washington	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	2,008,000
18183	Partnership for Supply Chain Management	Private Contractor	U.S. Agency for International Development	GHP-USAID	0
18184	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	0
18185	Davis Memorial Hospital and Clinic	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
18186	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	0
18187	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-USAID	1,000,000
18188	Caribbean Regional Public Health Agency	Parastatal	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	0



			Control and Prevention		
18189	TBD	TBD	Redacted	Redacted	Redacted
18190	Ministry of Health, Guyana	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
18392	Barbados MOH	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1
18393	Bahamas MoH	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	270,000
18394	Trinidad MoH	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1
18395	TBD	TBD	Redacted	Redacted	Redacted
18396	Caribbean Regional Public Health Agency	Parastatal	U.S. Department of Health and Human Services/Centers	GHP-State	369,000



			for Disease Control and Prevention		
18398	Global Data Analysis and Technical Assistance	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	545,157
18405	American Society of Clinical Pathology	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,262,000
18406	TBD	TBD	Redacted	Redacted	Redacted
18427	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State, GHP-USAID	1,233,936



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 12542	Mechanism Name: University of California, San Francisco (UCSF-SITAC) CoAg GH000977
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Jamaica	100,000
Suriname	125,000
Trinidad and Tobago	50,000
Guyana	0

Total All Funding Sources: 300,000		
Applied Pipeline Amount: 50,000		
Total All Funding Sources and Applied Pipeline Amount: 350,000		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	300,000

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	5,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Key Populations: FSW	20,000
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	250,000
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners

Budget Code Information

Mechanism ID: 12542			
Mechanism Name: University of California, San Francisco (UCSF-SITAC) CoAg GH000977			
Prime Partner Name: University of California at San Francisco			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	300,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12567	Mechanism Name: Jamaica MOH
Funding Agency: USAID	Procurement Type: Grant



Prime Partner Name: Jamaica Ministry of Health (MOH)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: USAID

Benefiting Country	Benefiting Country Planned Amount
Jamaica	0

Total All Funding Sources: 3,105,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 3,105,000		
Managing Country	Funding Source	Funding Amount
Jamaica	GHP-State	3,105,000

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	1,500,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	750,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention



Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs

Budget Code Information

Mechanism ID: 12567			
Mechanism Name: Jamaica MOH			
Prime Partner Name: Jamaica Ministry of Health (MOH)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,775,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	105,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	280,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	145,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	800,000	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Jamaica	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,909
Jamaica	KP_PREV_DSD	Total estimated number of key population in the catchment area	31,807
Jamaica	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,092
Jamaica	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	817
Jamaica	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	18,190
Jamaica	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	13,617
Jamaica	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,717
Jamaica	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	982



Jamaica	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	735
Jamaica	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,717
Jamaica	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,717
Jamaica	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	98
Jamaica	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	22
Jamaica	HTC_TST_DSD	Service Delivery Point (Community): Other	1,717
Jamaica	TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	12,728
Jamaica	TX_CURR_TA	Aggregated Age/Sex: 15+ Male	6,108
Jamaica	TX_CURR_TA	Aggregated Age/Sex: 15+ Female	6,620
Jamaica	TX_CURR_TA	Sum of Aggregated Age/Sex 15+	12,728
Jamaica	TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	12,728
Jamaica	TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,220
Jamaica	TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	585
Jamaica	TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	635
Jamaica	TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,220
Jamaica	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	770
Jamaica	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	377
Jamaica	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	393
Jamaica	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	770
Jamaica	INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	4,575
Jamaica	INVS_COMD	Number of HIV Test Kits purchased	1,889



Jamaica	INVS_COMD	Number of HIV Viral Load Reagents purchased	1,343
Jamaica	INVS_COMD	Number of HIV ARVs purchased	1,343
Jamaica	INVS_COMD	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	10,198
Jamaica	INVS_COMD	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	80,580
Jamaica	INVS_COMD	HIV ARVs: Dollars planned (COP)/ spent (Actual)	161,160

Implementing Mechanism Details

Mechanism ID: 12570	Mechanism Name: Bahamas MOH
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Bahamas MoH	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Benefiting Country	Benefiting Country Planned Amount
Bahamas	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 12570			
Mechanism Name: Bahamas MOH			
Prime Partner Name: Bahamas MoH			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Bahamas	INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	1,333
Bahamas	INVS_COMD	Number of HIV Viral Load Reagents purchased	1,333
Bahamas	INVS_COMD	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	40,000

Implementing Mechanism Details

Mechanism ID: 12575	Mechanism Name: PAHO/PHCO Cooperative Agreement--CK000346
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Pan American Health Organization (PAHO)/PAHO HIV Caribbean Office (PHCO)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
--------------------	-----------------------------------



Barbados	350,000
Guyana	0

Total All Funding Sources: 350,000		
Applied Pipeline Amount: 150,000		
Total All Funding Sources and Applied Pipeline Amount: 500,000		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	350,000

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	50,000
Focus Area:	Collection and use of strategic information on SWs and clients
Key Populations: MSM and TG	50,000
Focus Area:	Collection and use of strategic information

Budget Code Information

Mechanism ID:	12575		
Mechanism Name:	PAHO/PHCO Cooperative Agreement--CK000346		
Prime Partner Name:	Pan American Health Organization (PAHO)/PAHO HIV Caribbean Office (PHCO)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	115,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	235,000	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12587	Mechanism Name: PEPFAR Small Grants Program
Funding Agency: State/WHA	Procurement Type: Grant
Prime Partner Name: US Embassies	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Antigua and Barbuda	0
Bahamas	0
Barbados	0
Dominica	0
Grenada	0
Jamaica	0
St. Kitts and Nevis	0
St. Lucia	0
Suriname	0
Trinidad and Tobago	0
St. Vincent and the Grenadines	0

Total All Funding Sources: 200,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 200,000		
Managing Country	Funding Source	Funding Amount
Bahamas	GHP-State	30,000



Barbados	GHP-State	50,000
Jamaica	GHP-State	60,000
Suriname	GHP-State	30,000
Trinidad and Tobago	GHP-State	30,000

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	100,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Monitoring and evaluation of MSM/TG programs
Gender: GBV	40,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information

Budget Code Information

Mechanism ID: 12587 Mechanism Name: PEPFAR Small Grants Program Prime Partner Name: US Embassies			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 12588	Mechanism Name: CARICOM/PANCAP
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Caribbean Community (CARICOM) Pan Caribbean Partnership Against AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Antigua and Barbuda	0
Bahamas	0
Barbados	0
Dominica	0
Grenada	0
Jamaica	0
St. Kitts and Nevis	0
St. Lucia	0
Suriname	0
Trinidad and Tobago	0
St. Vincent and the Grenadines	0
Guyana	0

Total All Funding Sources: 200,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 200,000		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-USAID	200,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	50,000
-------------	--------



Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Human Resources for Health	50,000
Key Populations: FSW	50,000
Focus Area:	Collection and use of strategic information on SWs and clients
Key Populations: MSM and TG	50,000
Focus Area:	Collection and use of strategic information

Budget Code Information

Mechanism ID:	12588		
Mechanism Name:	CARICOM/PANCAP		
Prime Partner Name:	Caribbean Community (CARICOM) Pan Caribbean Partnership Against AIDS		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	70,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	70,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 12594	Mechanism Name: SI Regional Training
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: HRM	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Jamaica	2,083
Antigua and Barbuda	2,084
Bahamas	2,084
Barbados	2,084
Dominica	2,084
Grenada	2,083
Guyana	2,083
St. Kitts and Nevis	2,083
St. Lucia	2,083
St. Vincent and the Grenadines	2,083
Suriname	2,083
Trinidad and Tobago	2,083

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	0

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	0
----------------------	---



Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	0
Focus Area:	Monitoring and evaluation of MSM/TG programs

Budget Code Information

Mechanism ID: 12594 Mechanism Name: SI Regional Training Prime Partner Name: HRM			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12606	Mechanism Name: Barbados MOH CoAg GH000637
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Barbados MOH	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Benefiting Country	Benefiting Country Planned Amount
Barbados	0

Total All Funding Sources: 0		
-------------------------------------	--	--



Applied Pipeline Amount: 199,999		
Total All Funding Sources and Applied Pipeline Amount: 199,999		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12606			
Mechanism Name: Barbados MOH CoAg GH000637			
Prime Partner Name: Barbados MOH			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0



Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Barbados	INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	500
Barbados	INVS_COMD	Number of HIV Viral Load Reagents purchased	500
Barbados	INVS_COMD	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	25,000

Implementing Mechanism Details

Mechanism ID: 12642	Mechanism Name: Central Laboratory Support
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Jamaica	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	0



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12642		
Mechanism Name:	Central Laboratory Support		
Prime Partner Name:	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12645	Mechanism Name: Caribbean HIV Grants, Solicitation and Management Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: World Learning	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Bahamas	0
Jamaica	0

Total All Funding Sources: 0		
-------------------------------------	--	--



Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Jamaica	GHP-USAID	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12645		
Mechanism Name:	Caribbean HIV Grants, Solicitation and Management Project		
Prime Partner Name:	World Learning		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12668	Mechanism Name: Trinidad and Tobago MOH (PS003108)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Trinidad MoH	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC



Total All Funding Sources: 0		
Applied Pipeline Amount: 199,999		
Total All Funding Sources and Applied Pipeline Amount: 199,999		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12668		
Mechanism Name:	Trinidad and Tobago MOH (PS003108)		
Prime Partner Name:	Trinidad MoH		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Trinidad and Tobago	INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	882
Trinidad and Tobago	INVS_COMD	Number of HIV Viral Load Reagents purchased	882
Trinidad and Tobago	INVS_COMD	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	30,000



Implementing Mechanism Details

Mechanism ID: 12688	Mechanism Name: CARPHA REPDU (formerly CHRC Caribbean Health Research Council)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Caribbean Regional Public Health Agency	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Bahamas	0
Barbados	0
Jamaica	0
Suriname	0
Trinidad and Tobago	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12688
Mechanism Name:	CARPHA REPDU (formerly CHRC Caribbean Health Research Council)
Prime Partner Name:	Caribbean Regional Public Health Agency



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12971	Mechanism Name: HVOP -Prevention
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Jamaica	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Jamaica	GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 12971			
Mechanism Name: HVOP -Prevention			
Prime Partner Name: U.S. Peace Corps			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13319	Mechanism Name: Health Policy Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Futures Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Antigua and Barbuda	0
Barbados	0
Dominica	0
Grenada	0
Jamaica	0
St. Kitts and Nevis	0
St. Lucia	0
St. Vincent and the Grenadines	0

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-USAID	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13319		
Mechanism Name:	Health Policy Project		
Prime Partner Name:	Futures Group		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13335	Mechanism Name: Regional Laboratory Accreditation
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Field Epidemiology Network	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Benefiting Country	Benefiting Country Planned Amount
Antigua and Barbuda	0
Bahamas	0
Barbados	0
Dominica	0
Grenada	0
Jamaica	0
St. Kitts and Nevis	0
St. Lucia	0
Suriname	0
Trinidad and Tobago	0
St. Vincent and the Grenadines	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13335		
Mechanism Name:	Regional Laboratory Accreditation		
Prime Partner Name:	African Field Epidemiology Network		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13534	Mechanism Name: NASTAD CoAg GH001508
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Alliance of State and Territorial AIDS Directors	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Trinidad and Tobago	250,000
Guyana	0

Total All Funding Sources: 250,000		
Applied Pipeline Amount: 100,000		
Total All Funding Sources and Applied Pipeline Amount: 350,000		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	250,000

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	150,000
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients



Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	100,000
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs

Budget Code Information

Mechanism ID:	13534		
Mechanism Name:	NASTAD CoAg GH001508		
Prime Partner Name:	National Alliance of State and Territorial AIDS Directors		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	250,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13593	Mechanism Name: Suriname MOH CoAg GH000640
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: SURINAME MOH	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC



Benefiting Country	Benefiting Country Planned Amount
Barbados	1

Total All Funding Sources: 1		
Applied Pipeline Amount: 194,999		
Total All Funding Sources and Applied Pipeline Amount: 195,000		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	1

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	1
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs

Budget Code Information

Mechanism ID:	13593		
Mechanism Name:	Suriname MOH CoAg GH000640		
Prime Partner Name:	SURINAME MOH		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	1	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Suriname	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	288
Suriname	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	144
Suriname	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	144
Suriname	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	288
Suriname	INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	1,034
Suriname	INVS_COMD	Number of HIV Viral Load Reagents purchased	1,034
Suriname	INVS_COMD	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	30,000

Implementing Mechanism Details

Mechanism ID: 16482	Mechanism Name: PSI Caribbean
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Population Services International	

Approved



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Suriname	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 400,000		
Total All Funding Sources and Applied Pipeline Amount: 400,000		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16482			
Mechanism Name: PSI Caribbean			
Prime Partner Name: Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Suriname	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	805
Suriname	KP_PREV_DSD	Total estimated number of key population in the catchment area	5,160
Suriname	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	315
Suriname	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	490
Suriname	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	4,000
Suriname	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	1,160
Suriname	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	255
Suriname	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	95



		PERMISSION ONLY: 15+ Male	
Suriname	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	160
Suriname	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	255
Suriname	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	255
Suriname	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	10
Suriname	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	8
Suriname	HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	255
Suriname	HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	95
Suriname	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10
Suriname	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	85
Suriname	HTC_TST_TA	Sum of Aggregated Age/Sex 15+	95
Suriname	HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	95
Suriname	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	1
Suriname	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	4
Suriname	HTC_TST_TA	Service Delivery Point (Facility): VCT	95

Implementing Mechanism Details

Mechanism ID: 16661	Mechanism Name: CARPHA support CoAg GH001205
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Caribbean Regional Public Health Agency	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Benefiting Country	Benefiting Country Planned Amount
Antigua and Barbuda	3,000
Bahamas	45,000
Barbados	45,000
Dominica	3,000
Grenada	3,000
Jamaica	146,000
St. Kitts and Nevis	3,000
St. Lucia	3,000
Suriname	45,500
Trinidad and Tobago	65,438
St. Vincent and the Grenadines	5,000

Total All Funding Sources: 366,938		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 366,938		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	366,938

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Capacity building
Human Resources for Health	50,000



Key Populations: MSM and TG	25,000
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs

Budget Code Information

Mechanism ID: 16661			
Mechanism Name: CARPHA support CoAg GH001205			
Prime Partner Name: Caribbean Regional Public Health Agency			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	56,680	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	310,258	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17366	Mechanism Name: Linkages
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
--------------------	-----------------------------------



Bahamas	0
Barbados	0
Suriname	0
Trinidad and Tobago	0

Total All Funding Sources: 1,674,565		
Applied Pipeline Amount: 1,000,535		
Total All Funding Sources and Applied Pipeline Amount: 2,675,100		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-USAID	1,674,565

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	360,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	240,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach



	workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID: 17366			
Mechanism Name: Linkages			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	502,370	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	OHSS	167,455	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	251,185	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	251,185	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	502,370	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Bahamas	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,102
Bahamas	KP_PREV_DSD	Total estimated number of key population in the catchment area	4,409
Bahamas	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	372
Bahamas	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards)	730

		required)	
Bahamas	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	1,489
Bahamas	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	2,920
Bahamas	HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	882
Bahamas	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	294
Bahamas	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	588
Bahamas	HTC_TST_TA	Sum of Aggregated Age/Sex 15+	882
Bahamas	HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	882
Bahamas	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	18
Bahamas	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	30
Bahamas	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	48
Bahamas	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	18
Bahamas	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	30
Bahamas	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	48
Suriname	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	540

Suriname	KP_PREV_DSD	Total estimated number of key population in the catchment area	4,100
Suriname	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	280
Suriname	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	260
Suriname	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	2,800
Suriname	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	1,300
Suriname	HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	432
Suriname	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	224
Suriname	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	208
Suriname	HTC_TST_TA	Sum of Aggregated Age/Sex 15+	432
Suriname	HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	432
Suriname	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	13



Suriname	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	10
Suriname	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	23
Suriname	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	13
Suriname	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	10
Suriname	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	23
Trinidad and Tobago	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,000
Trinidad and Tobago	KP_PREV_DSD	Total estimated number of key population in the catchment area	17,444
Trinidad and Tobago	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	400
Trinidad and Tobago	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	600
Trinidad and Tobago	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	6,616
Trinidad and Tobago	KP_PREV_DSD	By key population type: Female sex	10,828



		workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
Trinidad and Tobago	HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	600
Trinidad and Tobago	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	360
Trinidad and Tobago	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	240
Trinidad and Tobago	HTC_TST_TA	Sum of Aggregated Age/Sex 15+	600
Trinidad and Tobago	HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	600
Trinidad and Tobago	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	22
Trinidad and Tobago	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	12
Trinidad and Tobago	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	36
Trinidad and Tobago	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	23
Trinidad and Tobago	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	13
Trinidad and Tobago	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	36

Implementing Mechanism Details

Mechanism ID: 17469	Mechanism Name: Health Finance and Governance
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Approved



Benefiting Country	Benefiting Country Planned Amount
Bahamas	0
Barbados	0
Suriname	0
Trinidad and Tobago	0
Guyana	0

Total All Funding Sources: 675,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 675,000		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-USAID	675,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17469		
Mechanism Name:	Health Finance and Governance		
Prime Partner Name:	Abt Associates		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	675,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 17760	Mechanism Name: Linkages
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Jamaica	0

Total All Funding Sources: 845,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 845,000		
Managing Country	Funding Source	Funding Amount
Jamaica	GHP-State	845,000

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	845,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other



	commodities essential to core HIV services for MSM/TG
--	---

Budget Code Information

Mechanism ID:	17760		
Mechanism Name:	Linkages		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	625,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	145,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	75,000	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Jamaica	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	176
Jamaica	KP_PREV_DSD	Total estimated number of key population in the catchment area	564
Jamaica	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations	176



		reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
Jamaica	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	564
Jamaica	KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	118
Jamaica	KP_PREV_TA	Total estimated number of key population in the catchment area	376
Jamaica	KP_PREV_TA	By key population type: Men who have sex with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	118
Jamaica	KP_PREV_TA	By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	376
Jamaica	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	142
Jamaica	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	142
Jamaica	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	142
Jamaica	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	142
Jamaica	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	22



Jamaica	HTC_TST_DSD	Service Delivery Point (Community): Other	82
Jamaica	HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	94
Jamaica	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	94
Jamaica	HTC_TST_TA	Sum of Aggregated Age/Sex 15+	94
Jamaica	HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	94
Jamaica	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	14
Jamaica	HTC_TST_TA	Service Delivery Point (Community): Other	14
Jamaica	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	22
Jamaica	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	22
Jamaica	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	22

Implementing Mechanism Details

Mechanism ID: 17808	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17809	Mechanism Name: Knowledge for Health II
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Johns Hopkins University Center for Communication Programs	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Antigua and Barbuda	0



Bahamas	0
Barbados	0
Dominica	0
Grenada	0
Jamaica	0
St. Kitts and Nevis	0
St. Lucia	0
Suriname	0
Trinidad and Tobago	0
St. Vincent and the Grenadines	0
Guyana	0

Total All Funding Sources: 350,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 350,000		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-USAID	350,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Post GBV Care
Human Resources for Health	50,000
Key Populations: FSW	100,000
Focus Area:	Collection and use of strategic information on SWs and clients
Key Populations: MSM and TG	100,000
Focus Area:	Collection and use of strategic information



Budget Code Information

Mechanism ID: 17809			
Mechanism Name: Knowledge for Health II			
Prime Partner Name: Johns Hopkins University Center for Communication Programs			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	122,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	52,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	52,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	122,500	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17810	Mechanism Name: Grant Management Solutions
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Benefiting Country	Benefiting Country Planned Amount
Antigua and Barbuda	0
Bahamas	0
Barbados	0
Dominica	0
Grenada	0
Jamaica	0
St. Kitts and Nevis	0
St. Lucia	0
Suriname	0
Trinidad and Tobago	0
St. Vincent and the Grenadines	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-USAID	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17810		
Mechanism Name:	Grant Management Solutions		
Prime Partner Name:	Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17878	Mechanism Name: Quarterly Consultation Meetings
Funding Agency: USAID	Procurement Type: USG Core
Prime Partner Name: US Embassies	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Bahamas	0
Barbados	0
Jamaica	0
Suriname	0
Trinidad and Tobago	0

Total All Funding Sources: 85,010		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 85,010		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	85,010

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	34,000
Focus Area:	Implementation of core HIV prevention interventions



	for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	20,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Gender: GBV	20,000
Focus Area:	GBV Prevention
Sub Area:	Implementation

Budget Code Information

Mechanism ID:	17878		
Mechanism Name:	Quarterly Consultation Meetings		
Prime Partner Name:	US Embassies		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	85,010	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17902	Mechanism Name: Health Policy Plus
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Palladium Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Benefiting Country	Benefiting Country Planned Amount
Jamaica	0

Total All Funding Sources: 710,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 710,000		
Managing Country	Funding Source	Funding Amount
Jamaica	GHP-State	710,000

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	360,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Key Populations: FSW	180,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients

Budget Code Information

Mechanism ID:	17902		
Mechanism Name:	Health Policy Plus		
Prime Partner Name:	Palladium Group		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	710,000	0
------	------	---------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17919	Mechanism Name: HIV Rapid Testing Quality Improvement Initiative (RTQII)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Jamaica	0
Suriname	0
Trinidad and Tobago	0
Antigua and Barbuda	0
Barbados	0
Dominica	0
Grenada	0
Guyana	0
St. Kitts and Nevis	0
St. Lucia	0
St. Vincent and the Grenadines	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount



Barbados	GHP-State	0
----------	-----------	---

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17919		
Mechanism Name:	HIV Rapid Testing Quality Improvement Initiative (RTQII)		
Prime Partner Name:	African Society for Laboratory Medicine		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Bahamas	LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Bahamas	LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	1
Bahamas	LAB_PT_TA	CD4: Number of laboratories that perform this testing	1
Bahamas	LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Bahamas	LAB_PT_TA	Early infant diagnostics: Number of	1



		laboratories that participate in this PT program	
Bahamas	LAB_PT_TA	Early infant diagnostics: Number of laboratories that perform this testing	1
Bahamas	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
Bahamas	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	4
Bahamas	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	4
Bahamas	LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Bahamas	LAB_PT_TA	HIV viral load: Number of laboratories that participate in this PT program	1
Bahamas	LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	1
Bahamas	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Bahamas	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	1
Bahamas	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	1
Bahamas	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
Bahamas	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT	0



		program	
Bahamas	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
Bahamas	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
Bahamas	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
Bahamas	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
Barbados	LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Barbados	LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	1
Barbados	LAB_PT_TA	CD4: Number of laboratories that perform this testing	1
Barbados	LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Barbados	LAB_PT_TA	Early infant diagnostics: Number of laboratories that participate in this PT program	1
Barbados	LAB_PT_TA	Early infant diagnostics: Number of laboratories that perform this testing	1
Barbados	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	5
Barbados	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	5



Barbados	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	5
Barbados	LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Barbados	LAB_PT_TA	HIV viral load: Number of laboratories that participate in this PT program	1
Barbados	LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	1
Barbados	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Barbados	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	1
Barbados	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	1
Barbados	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
Barbados	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
Barbados	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
Barbados	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
Barbados	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
Barbados	LAB_PT_TA	TB diagnostics (Culture/DST): Number of	0



		laboratories that perform this testing	
Jamaica	LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
Jamaica	LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	4
Jamaica	LAB_PT_TA	CD4: Number of laboratories that perform this testing	4
Jamaica	LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Jamaica	LAB_PT_TA	Early infant diagnostics: Number of laboratories that participate in this PT program	1
Jamaica	LAB_PT_TA	Early infant diagnostics: Number of laboratories that perform this testing	1
Jamaica	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	18
Jamaica	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	18
Jamaica	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	18
Jamaica	LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Jamaica	LAB_PT_TA	HIV viral load: Number of laboratories that participate in this PT program	1
Jamaica	LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	1
Jamaica	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable	6

		successful passing criteria in this PT program	
Jamaica	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	6
Jamaica	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	6
Jamaica	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
Jamaica	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
Jamaica	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
Jamaica	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
Jamaica	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
Jamaica	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
Suriname	LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Suriname	LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	1
Suriname	LAB_PT_TA	CD4: Number of laboratories that perform this testing	1
Suriname	LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT	1



		program	
Suriname	LAB_PT_TA	Early infant diagnostics: Number of laboratories that participate in this PT program	1
Suriname	LAB_PT_TA	Early infant diagnostics: Number of laboratories that perform this testing	1
Suriname	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	8
Suriname	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	8
Suriname	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	8
Suriname	LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Suriname	LAB_PT_TA	HIV viral load: Number of laboratories that participate in this PT program	1
Suriname	LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	1
Suriname	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
Suriname	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	3
Suriname	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	3
Suriname	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0

Suriname	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
Suriname	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
Suriname	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
Suriname	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
Suriname	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
Trinidad and Tobago	LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
Trinidad and Tobago	LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	4
Trinidad and Tobago	LAB_PT_TA	CD4: Number of laboratories that perform this testing	4
Trinidad and Tobago	LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Trinidad and Tobago	LAB_PT_TA	Early infant diagnostics: Number of laboratories that participate in this PT program	1
Trinidad and Tobago	LAB_PT_TA	Early infant diagnostics: Number of laboratories that perform this testing	1
Trinidad and Tobago	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
Trinidad and Tobago	LAB_PT_TA	HIV serologic/diagnostic testing: Number of	9

		laboratories that participate in this PT program	
Trinidad and Tobago	LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	9
Trinidad and Tobago	LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
Trinidad and Tobago	LAB_PT_TA	HIV viral load: Number of laboratories that participate in this PT program	1
Trinidad and Tobago	LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	1
Trinidad and Tobago	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	6
Trinidad and Tobago	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	6
Trinidad and Tobago	LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	6
Trinidad and Tobago	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
Trinidad and Tobago	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
Trinidad and Tobago	LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
Trinidad and Tobago	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
Trinidad and Tobago	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT	0



		program	
Trinidad and Tobago	LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0

Implementing Mechanism Details

Mechanism ID: 17921	Mechanism Name: International AIDS Education and Training Center
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Barbados	0
Jamaica	0
Suriname	0
Trinidad and Tobago	0

Total All Funding Sources: 2,008,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 2,008,000		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	2,008,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	50,065
----------------------------	--------



Budget Code Information

Mechanism ID: 17921			
Mechanism Name: International AIDS Education and Training Center			
Prime Partner Name: University of Washington			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	288,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	50,065	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,669,935	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Barbados	TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,578
Barbados	TX_CURR_TA	Aggregated Age/Sex: 15+ Male	899
Barbados	TX_CURR_TA	Aggregated Age/Sex: 15+ Female	679
Barbados	TX_CURR_TA	Sum of Aggregated Age/Sex 15+	1,578
Barbados	TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	1,578
Barbados	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	38
Barbados	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	22
Barbados	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	16
Barbados	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	38



Barbados	TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,262
Barbados	TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,578
Barbados	TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	719
Barbados	TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	543
Barbados	TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	899
Barbados	TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	679
Jamaica	TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	12,728
Jamaica	TX_CURR_TA	Aggregated Age/Sex: 15+ Male	6,109
Jamaica	TX_CURR_TA	Aggregated Age/Sex: 15+ Female	6,619
Jamaica	TX_CURR_TA	Sum of Aggregated Age/Sex 15+	12,728
Jamaica	TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	12,728
Jamaica	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,337
Jamaica	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	1,619
Jamaica	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	1,718
Jamaica	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	3,337
Jamaica	TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting	10,181



		laboratory results within the past 12 months.	
Jamaica	TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	12,728
Jamaica	TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	4,886
Jamaica	TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	5,295
Jamaica	TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	6,109
Jamaica	TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	6,619
Jamaica	HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	6
Suriname	TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	464
Suriname	TX_CURR_TA	Aggregated Age/Sex: 15+ Male	231
Suriname	TX_CURR_TA	Aggregated Age/Sex: 15+ Female	233
Suriname	TX_CURR_TA	Sum of Aggregated Age/Sex 15+	464
Suriname	TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	464
Suriname	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	55
Suriname	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	27
Suriname	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	28
Suriname	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	55
Suriname	TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the	325



		medical records and /or supporting laboratory results within the past 12 months.	
Suriname	TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	464
Suriname	TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	162
Suriname	TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	163
Suriname	TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	231
Suriname	TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	233
Suriname	HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	2
Trinidad and Tobago	TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,291
Trinidad and Tobago	TX_CURR_TA	Aggregated Age/Sex: 15+ Male	645
Trinidad and Tobago	TX_CURR_TA	Aggregated Age/Sex: 15+ Female	646
Trinidad and Tobago	TX_CURR_TA	Sum of Aggregated Age/Sex 15+	1,291
Trinidad and Tobago	TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	1,291
Trinidad and Tobago	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	133
Trinidad and Tobago	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	66
Trinidad and Tobago	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	67
Trinidad and Tobago	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	133
Trinidad and Tobago	TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results	1,162



		(<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	
Trinidad and Tobago	TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,291
Trinidad and Tobago	TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	581
Trinidad and Tobago	TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	581
Trinidad and Tobago	TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	645
Trinidad and Tobago	TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	646
Trinidad and Tobago	HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	4

Implementing Mechanism Details

Mechanism ID: 18183	Mechanism Name: The Partnership for Supply Chain Management
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Partnership for Supply Chain Management	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Bahamas	0
Barbados	0

Approved



Guyana	0
Suriname	0
Trinidad and Tobago	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-USAID	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18183			
Mechanism Name: The Partnership for Supply Chain Management			
Prime Partner Name: Partnership for Supply Chain Management			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18184	Mechanism Name: DoD Mech Guyana
Funding Agency: DOD	Procurement Type: USG Core
Prime Partner Name: U.S. Department of Defense (Defense)	

Approved



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Guyana	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 33,000		
Total All Funding Sources and Applied Pipeline Amount: 33,000		
Managing Country	Funding Source	Funding Amount
Guyana	GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18184			
Mechanism Name: DoD Mech Guyana			
Prime Partner Name: U.S. Department of Defense (Defense)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Prevention	HVOP	0	0
------------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18185	Mechanism Name: Positively United to Support Humanity
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Davis Memorial Hospital and Clinic	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Guyana	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Guyana	GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18185



Mechanism Name: Positively United to Support Humanity			
Prime Partner Name: Davis Memorial Hospital and Clinic			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information



OU	Indicator Number	Label	2017
Guyana	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,955
Guyana	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	71
Guyana	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	745
Guyana	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	67
Guyana	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,072
Guyana	HTC_TST_DSD	Sum of Aggregated Age/Sex <15	138
Guyana	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,817
Guyana	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,955
Guyana	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	3
Guyana	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	38
Guyana	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	3
Guyana	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	34
Guyana	HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	1,655
Guyana	HTC_TST_DSD	Service Delivery Point (Facility): Index testing	300
Guyana	TB_SCREENDX_DS D	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	1,718
Guyana	TB_SCREENDX_DS D	Screened for TB by Age/Sex:<15 Male	9
Guyana	TB_SCREENDX_DS D	Screened for TB by Age/Sex: 15+ Male	644
Guyana	TB_SCREENDX_DS	Screened for TB by Age/Sex:<15 Female	35

	D		
Guyana	TB_SCREENDX_DS D	Screened for TB by Age/Sex: 15+ Female	1,030
Guyana	TB_SCREENDX_DS D	Screen Result: Screened Positive for TB	35
Guyana	TB_SCREENDX_DS D	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	35
Guyana	TB_SCREENDX_DS D	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	27
Guyana	TB_SCREENDX_DS D	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	8
Guyana	PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	38
Guyana	PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	2
Guyana	PMTCT_EID_TA	Sum of Infant Age disaggregates	40
Guyana	PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	0
Guyana	PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	0
Guyana	TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,718
Guyana	TX_CURR_DSD	Aggregated Age/Sex: <15 Male	9
Guyana	TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	644
Guyana	TX_CURR_DSD	Aggregated Age/Sex: <15 Female	35
Guyana	TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,030
Guyana	TX_CURR_DSD	Sum of Aggregated Age/Sex <15	44
Guyana	TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,674
Guyana	TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,718
Guyana	TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	322
Guyana	TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	2



Guyana	TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	147
Guyana	TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	2
Guyana	TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	171
Guyana	TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	322
Guyana	TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,160
Guyana	TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,546
Guyana	TX_PVLS_DSD	Numerator: Indication: Routine	1,160
Guyana	TX_PVLS_DSD	Denominator: Indication: Routine	1,546
Guyana	TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	29
Guyana	TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	543
Guyana	TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	29
Guyana	TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	559
Guyana	TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	38
Guyana	TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	715
Guyana	TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	40
Guyana	TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	753
Guyana	TX_RET_DSD	Number of adults and children who are still	151



		alive and on treatment at 12 months after initiating ART	
Guyana	TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	178
Guyana	TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7
Guyana	TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	64
Guyana	TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8
Guyana	TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	72
Guyana	TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8
Guyana	TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those	76



		lost to follow-up)	
Guyana	TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10
Guyana	TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	84

Implementing Mechanism Details

Mechanism ID: 18186	Mechanism Name: Peace Corps
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Guyana	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 39,000		
Total All Funding Sources and Applied Pipeline Amount: 39,000		
Managing Country	Funding Source	Funding Amount
Guyana	GHP-State	0



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18186			
Mechanism Name: Peace Corps			
Prime Partner Name: U.S. Peace Corps			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18187	Mechanism Name: Advancing Partners and Communities Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
---------------------------	--



Guyana	0
--------	---

Total All Funding Sources: 1,000,000		
Applied Pipeline Amount: 300,000		
Total All Funding Sources and Applied Pipeline Amount: 1,300,000		
Managing Country	Funding Source	Funding Amount
Guyana	GHP-USAID	1,000,000

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	160,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	130,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID: 18187			
Mechanism Name: Advancing Partners and Communities Project			
Prime Partner Name: John Snow Inc (JSI)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	405,080	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	97,193	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	152,449	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	71,673	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	173,605	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Guyana	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,652
Guyana	KP_PREV_DSD	Total estimated number of key population in the catchment area	3,658
Guyana	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,286
Guyana	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,366
Guyana	KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	1,837



Guyana	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	1,821
Guyana	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,652
Guyana	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	12
Guyana	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,274
Guyana	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6
Guyana	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,360
Guyana	HTC_TST_DSD	Sum of Aggregated Age/Sex <15	18
Guyana	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	2,634
Guyana	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	2,652
Guyana	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	3
Guyana	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	61
Guyana	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1
Guyana	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	67
Guyana	HTC_TST_DSD	Service Delivery Point (Community): Index testing	150
Guyana	HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	1,739
Guyana	HTC_TST_DSD	Service Delivery Point (Community): Other	763
Guyana	OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	162



Guyana	OVC_SERV_DSD	Age/Sex: 18+ Male	52
Guyana	OVC_SERV_DSD	Age/Sex: 18+ Female	83
Guyana	OVC_SERV_DSD	Sum of Age/Sex disaggregates	135
Guyana	OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	12
Guyana	OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	15

Implementing Mechanism Details

Mechanism ID: 18188	Mechanism Name: CARPHA Guyana CoAg GH001642
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Caribbean Regional Public Health Agency	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0		
Applied Pipeline Amount: 250,000		
Total All Funding Sources and Applied Pipeline Amount: 250,000		
Managing Country	Funding Source	Funding Amount
Guyana	GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18188			
Mechanism Name: CARPHA Guyana CoAg GH001642			
Prime Partner Name: Caribbean Regional Public Health Agency			
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18189	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18190	Mechanism Name: Ministry of Health, Guyana CoAg GH001632	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Ministry of Health, Guyana		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: Yes	Managing Agency: HHS/CDC	

Total All Funding Sources: 0		
Applied Pipeline Amount: 500,000		
Total All Funding Sources and Applied Pipeline Amount: 500,000		
Managing Country	Funding Source	Funding Amount
Guyana	GHP-State	0

Cross-Cutting Budget Attribution(s)



(No data provided.)

Budget Code Information

Mechanism ID: 18190			
Mechanism Name: Ministry of Health, Guyana CoAg GH001632			
Prime Partner Name: Ministry of Health, Guyana			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Guyana	TB_SCREENDX_TA	The number of PLHIV who were screened	1,861



		for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	
Guyana	TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	100
Guyana	TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	837
Guyana	TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	94
Guyana	TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	830
Guyana	TB_SCREENDX_TA	Screen Results: Screened Positive for TB	38
Guyana	TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	38
Guyana	TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	29
Guyana	TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	9
Guyana	TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,861
Guyana	TX_CURR_TA	Aggregated Age/Sex: <15 Male	94
Guyana	TX_CURR_TA	Aggregated Age/Sex: 15+ Male	830
Guyana	TX_CURR_TA	Aggregated Age/Sex: <15 Female	100
Guyana	TX_CURR_TA	Aggregated Age/Sex: 15+ Female	837
Guyana	TX_CURR_TA	Sum of Aggregated Age/Sex <15	194
Guyana	TX_CURR_TA	Sum of Aggregated Age/Sex 15+	1,667
Guyana	TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	1,861
Guyana	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	349
Guyana	TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	2
Guyana	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	163
Guyana	TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	2
Guyana	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	182



Guyana	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	349
Guyana	TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,256
Guyana	TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,675
Guyana	TX_PVLS_TA	Numerator: Indication: Routine	1,256
Guyana	TX_PVLS_TA	Denominator: Indication: Routine	1,675
Guyana	TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	51
Guyana	TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	549
Guyana	TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	73
Guyana	TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	583
Guyana	TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	77
Guyana	TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	745
Guyana	TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	91
Guyana	TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	762
Guyana	TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	200
Guyana	TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	227



		stopped ART, and those lost to follow-up	
Guyana	TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
Guyana	TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	86
Guyana	TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
Guyana	TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	94
Guyana	TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9
Guyana	TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	95
Guyana	TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	14



		those who have stopped ART, and those lost to follow-up)	
Guyana	TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	109

Implementing Mechanism Details

Mechanism ID: 18392	Mechanism Name: Barbados MOH FOA GH16-1610 (Follow-on to CoAg GH000637)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Barbados MOH	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: Yes	Managing Agency: HHS/CDC

Benefiting Country	Benefiting Country Planned Amount
Barbados	1

Total All Funding Sources: 1		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 1		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	1

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 18392			
Mechanism Name: Barbados MOH FOA GH16-1610 (Follow-on to CoAg GH000637)			
Prime Partner Name: Barbados MOH			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Barbados	TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	164
Barbados	TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	82
Barbados	TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	82



Barbados	TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	164
Barbados	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	120
Barbados	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	60
Barbados	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	60
Barbados	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	120

Implementing Mechanism Details

Mechanism ID: 18393	Mechanism Name: Bahamas MOH FOA GH16-1609 (Follow-on to CoAg PS002934)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Bahamas MoH	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: Yes	Managing Agency: HHS/CDC

Benefiting Country	Benefiting Country Planned Amount
Bahamas	270,000

Total All Funding Sources: 270,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 270,000		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	270,000

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	80,000
Focus Area:	Training of health workers and community outreach workers



Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	80,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs

Budget Code Information

Mechanism ID:	18393		
Mechanism Name:	Bahamas MOH FOA GH16-1609 (Follow-on to CoAg PS002934)		
Prime Partner Name:	Bahamas MoH		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	37,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	80,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	52,500	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Bahamas	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	192
Bahamas	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	96
Bahamas	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	96
Bahamas	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	192

Implementing Mechanism Details

Mechanism ID: 18394	Mechanism Name: Trinidad and Tobago MOH FOA GH16-1608 (follow up to CoAg PS003108)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Trinidad MoH	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: Yes	Managing Agency: HHS/CDC

Benefiting Country	Benefiting Country Planned Amount
Trinidad and Tobago	1

Total All Funding Sources: 1		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 1		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	1

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18394		
Mechanism Name:	Trinidad and Tobago MOH FOA GH16-1608 (follow up to CoAg PS003108)		
Prime Partner Name:	Trinidad MoH		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Trinidad and Tobago	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	555
Trinidad and Tobago	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	285
Trinidad and Tobago	TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	270
Trinidad and Tobago	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	555

Implementing Mechanism Details

Mechanism ID: 18395	Mechanism Name: CDC Prevention FOA GH16-1607
Funding Agency: HHS/CDC	Procurement Type: Umbrella Agreement
Prime Partner Name: TBD	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
--------------------	-----------------------------------



Bahamas	1
Barbados	0
Jamaica	0
Suriname	0
Trinidad and Tobago	0
Guyana	0

Total All Funding Sources: 1		
Applied Pipeline Amount: 596,699		
Total All Funding Sources and Applied Pipeline Amount: 596,700		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	1

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18395		
Mechanism Name:	CDC Prevention FOA GH16-1607		
Prime Partner Name:	TBD		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1	0



Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
Jamaica	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	108
Jamaica	TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	80
Jamaica	TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	26
Jamaica	TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	106
Jamaica	INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	1,724
Jamaica	INVS_COMD	Number of HIV Viral Load Reagents purchased	1,724
Jamaica	INVS_COMD	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	50,000
Trinidad and Tobago	INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	882
Trinidad and Tobago	INVS_COMD	Number of HIV Viral Load Reagents purchased	882
Trinidad and Tobago	INVS_COMD	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	30,000

Implementing Mechanism Details

Mechanism ID: 18396	Mechanism Name: CARPHA REPDU FOA GH16-1611 (Follow-on to CoAg GH000688)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Caribbean Regional Public Health Agency	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Antigua and Barbuda	4,000
Bahamas	25,000
Barbados	25,000
Dominica	4,000
Grenada	4,000
Jamaica	170,000
St. Kitts and Nevis	4,000
St. Lucia	4,000
St. Vincent and the Grenadines	4,000
Suriname	25,000
Trinidad and Tobago	100,000

Total All Funding Sources: 369,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 369,000		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	369,000

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	100,000
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	100,000
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs



Budget Code Information

Mechanism ID:	18396		
Mechanism Name:	CARPHA REPDU FOA GH16-1611 (Follow-on to CoAg GH000688)		
Prime Partner Name:	Caribbean Regional Public Health Agency		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	369,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18398	Mechanism Name: GDATA
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: Global Data Analysis and Technical Assistance	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Guyana	220,157
Barbados	325,000

Total All Funding Sources: 545,157		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 545,157		



Managing Country	Funding Source	Funding Amount
Guyana	GHP-State	220,157
Barbados	GHP-State	325,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18398		
Mechanism Name:	GDATA		
Prime Partner Name:	Global Data Analysis and Technical Assistance		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	545,157	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18405	Mechanism Name: HQ Lab FOA GH16-1689 (Follow on to AFENET CoAg PS 002728)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society of Clinical Pathology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:



Benefiting Country	Benefiting Country Planned Amount
Antigua and Barbuda	5,000
Barbados	80,000
Dominica	5,000
Grenada	5,000
Guyana	0
Jamaica	563,000
St. Kitts and Nevis	5,000
St. Lucia	5,000
St. Vincent and the Grenadines	5,000
Suriname	200,000
Trinidad and Tobago	389,000

Total All Funding Sources: 1,262,000		
Applied Pipeline Amount: 200,000		
Total All Funding Sources and Applied Pipeline Amount: 1,462,000		
Managing Country	Funding Source	Funding Amount
Barbados	GHP-State	1,262,000

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	100,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Capacity building
Human Resources for Health	100,000

Budget Code Information



Mechanism ID: 18405			
Mechanism Name: HQ Lab FOA GH16-1689 (Follow on to AFENET CoAg PS 002728)			
Prime Partner Name: American Society of Clinical Pathology			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,262,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18406	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18427	Mechanism Name: Global Health Supply Chain Program
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Jamaica	0
Bahamas	0
Barbados	0
Suriname	0
Trinidad and Tobago	0



Total All Funding Sources: 1,233,936		
Applied Pipeline Amount: 266,064		
Total All Funding Sources and Applied Pipeline Amount: 1,500,000		
Managing Country	Funding Source	Funding Amount
Jamaica	GHP-State	100,000
Guyana	GHP-USAID	226,787
Barbados	GHP-USAID	226,788
Suriname	GHP-USAID	226,786
Trinidad and Tobago	GHP-USAID	226,787
Bahamas	GHP-USAID	226,788

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18427		
Mechanism Name:	Global Health Supply Chain Program		
Prime Partner Name:	Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,233,936	0

Implementing Mechanism Indicator Information

(No data provided.)



Agency Information - Costs of Doing Business
U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services			110,119	50,408	110,119	160,527
ICASS			287,157	124,268	287,157	411,425
Management Meetings/Professional Development			145,966	129,928	145,966	275,894
Non-ICASS Administrative Costs			35,694	16,646	35,694	52,340
Staff Program Travel			155,344	143,192	155,344	298,536
USG Staff Salaries and Benefits - Internationally Recruited			210,443	108,971	210,443	319,414
USG Staff Salaries and Benefits - Locally Recruited			558,404	781,242	558,404	1,339,646
Total	0	0	1,503,127	1,354,655	1,503,127	2,857,782



U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		0		5,000	0	5,000
ICASS		0		45,000	0	45,000
Indirect Costs		0		20,000	0	20,000
Institutional Contractors				35,000	0	35,000
Management Meetings/Professional Development		0		10,000	0	10,000
Staff Program Travel		0		75,000	0	75,000
USG Staff Salaries and Benefits - Locally Recruited		0		175,000	0	175,000
Total	0	0	0	365,000	0	365,000

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of
----------------------	-----	-----------	-----------	------------------	-------	-------------------



Business						Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing	9,900	336,231		15,694	346,131	361,825
Computers/IT Services	30,000	30,000		0	60,000	60,000
ICASS	72,175	633,400		114,425	705,575	820,000
Institutional Contractors		458,000		0	458,000	458,000
Management Meetings/Professional Development	4,701	79,100		7,453	83,801	91,254
Non-ICASS Administrative Costs	7,343	29,025		11,641	36,368	48,009
Staff Program Travel	27,632	246,800		43,808	274,432	318,240
USG Staff Salaries and Benefits - Internationally Recruited	1,018,750	416,499		0	1,435,249	1,435,249
USG Staff Salaries and Benefits - Locally Recruited	83,249	746,557		131,979	829,806	961,785
Total	1,253,750	2,975,612	0	325,000	4,229,362	4,554,362



U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
ICASS		0		9,650	0	9,650
Management Meetings/Professional Development		0		12,785	0	12,785
Staff Program Travel		0		12,786	0	12,786
USG Staff Salaries and Benefits - Internationally Recruited		399,544		0	399,544	399,544
USG Staff Salaries and Benefits - Locally Recruited		0		59,741	0	59,741
Total	0	399,544	0	94,962	399,544	494,506

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business
-------------------------------	-----	-----------	-----------	------------------	-------	----------------------------------

Approved



						Categories and Applied Pipeline Amount
Non-ICASS Administrative Costs		0		2,000	0	2,000
Peace Corps Volunteer Costs		0		68,587	0	68,587
Staff Program Travel		0		10,000	0	10,000
Total	0	0	0	80,587	0	80,587